|
Carcinoma of lung
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
17beta-Estradiol decreased DNMT1 and HDAC1 protein expressions and their binding activity on MGMT promoter, and this may partially contribute to the gender difference of MGMT hypermethylation in lung cancer.
|
19596925 |
2009 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings may indicate the involvement of SNIP1 in progression of lung cancer by regulating the RB/HDAC1 interaction.
|
23932364 |
2013 |
|
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Finally, HDAC1 mRNA or protein expression was negatively correlated with the overall survival rate of patients with lung cancer (HR = 2.40, 95% CI = 1.48-3.88, P = .0004).
|
28767587 |
2017 |
|
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our data show coordinated transcription of HDAC1 and HDAC2 in lung cancer cell lines, but suggest HDAC2 protein expression is cell-context specific.
|
25970771 |
2015 |
|
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of HDAC1 and uPAR shows the minimal expression pattern in control and initial stages of lung cancer, but its expression increased in advanced stage of cancer.
|
30280780 |
2018 |
|
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Histone deacetylase 1 represses the small GTPase RhoB expression in human nonsmall lung carcinoma cell line.
|
13679859 |
2003 |
|
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The HDAC1/GAPDH mRNA levels were significantly higher in stage III or IV lung cancer (50.929 +/- 120.433) than in stage I lung cancer (11.430 +/- 25.611, P = 0.0472).
|
15474665 |
2004 |
|
Carcinoma, Basal Cell
|
0.010 |
Biomarker
|
disease |
BEFREE |
The GLI1 transcription factor must maintain maximal Hedgehog pathway output in basal cell carcinomas (BCCs), and we have previously shown that resistant BCCs increase GLI1 deacetylation through atypical protein kinase Cι/λ (aPKC) and HDAC1.
|
30503211 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.030 |
Biomarker
|
disease |
BEFREE |
Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance.
|
24475290 |
2014 |
|
Carcinoma, Ovarian Epithelial
|
0.030 |
Biomarker
|
disease |
BEFREE |
Small interfering RNA (siRNA)-targeting HDAC1 was designed to silence HDAC1 in the cisplatin-resistant ovarian cancer cell line A2780CDDP and its cisplatin-sensitive cell line A2780.
|
30071534 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.030 |
Biomarker
|
disease |
BEFREE |
Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer.
|
27694895 |
2017 |
|
Carcinoma, Papillary
|
0.010 |
Biomarker
|
disease |
BEFREE |
The cellular pattern of HDAC-1 and HDAC-2 distribution (nuclear vs. nuclear and cytoplasmic) presented a distinct discrimination between malignant and benign thyroid lesions (p = 0.0030 and p = 0.0028, respectively) as well as between papillary carcinoma and hyperplastic nodules (p = 0.0036 and p = 0.0028, respectively).
|
23873102 |
2014 |
|
Carcinoma, Transitional Cell
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We determined dose response curves of 4SC-202 by MTT assay in seven UC cell lines with distinct HDAC1, HDAC2 and HDAC3 expression profiles.
|
27250763 |
2016 |
|
Carcinoma, Transitional Cell
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Class I histone deacetylases HDAC1 and HDAC2 contribute to cell proliferation and are commonly upregulated in urothelial carcinoma.
|
26772204 |
2016 |
|
Cardiac fibrosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our results showed that ellagic acid significantly reduced protein expression of HDAC1, mRNA expression of collagen I, collagen III, MMP-2 and MMP-9 and the area of cardiac fibrosis in MI rats.
|
31168029 |
2019 |
|
Cardiomyopathy, Familial Idiopathic
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Altogether, our in vitro and in vivo data indicate that the ERBB2 gene is a novel MBP-1 target, and immunohistochemistry analysis of primary tumors suggests that the concomitant high expression of MBP-1 and HDAC1 may be considered a diagnostic marker of cancer progression for breast IDC.
|
23421821 |
2013 |
|
Central neuroblastoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
We have now extended our work and shown that, unlike NEP, another amyloid-degrading enzyme, IDE, is not related to over-expression of APP695 in neuroblastoma SH-SY5Y cells but is up-regulated by APP751 and APP770 isoforms independently of AICD but correlating with reduced HDAC1 binding to its promoter.
|
26376806 |
2016 |
|
Central neuroblastoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
High HDAC1 mRNA expression was associated with multidrug resistance in neuroblastoma cell lines, and inhibition of HDAC1 expression or activity enhanced the cytotoxicity of chemotherapeutic drugs in multidrug-resistant neuroblastoma cell lines.
|
17623797 |
2007 |
|
Central neuroblastoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Further investigation demonstrated that selective HDAC1/HDAC2 inhibition using compounds or RNA interference induced differentiation and decreased viability in neuroblastoma cell lines.
|
23706636 |
2013 |
|
Central neuroblastoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF.
|
21123453 |
2011 |
|
Central neuroblastoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
We have investigated the mRNA expression of all HDAC1-11 family members in a large cohort of primary neuroblastoma samples covering the full spectrum of the disease.
|
19118036 |
2009 |
|
Central Serous Chorioretinopathy
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, we determine that HDAC1 and HDAC7 are necessary to maintain CSCs, and that over-expression of HDAC7 is sufficient to augment the CSC phenotype.
|
27694895 |
2017 |
|
Cerebrovascular accident
|
0.210 |
Biomarker
|
group |
BEFREE |
Collectively, these results demonstrate that NCX1 expression is regulated by the Sp3/REST/HDAC1/HDAC2 complex in tMCAO and by the Sp1/HIF-1/p300 complex in PC+tMCAO and that epigenetic intervention, by modulating the acetylation of ncx1-Br, may be a strategy for the development of innovative therapeutic intervention in stroke.
|
25972164 |
2015 |
|
Cerebrovascular accident
|
0.210 |
Biomarker
|
group |
RGD |
Double immunohistochemistry analysis revealed that stroke substantially increased the number of NG2+OPCs with nuclear HDAC1 and HDAC2 immunoreactivity and cytoplasmic HDAC4 which were associated with augmentation of proliferating OPCs, as determined by BrdU and Ki67 double reactive cells after stroke.
|
24657831 |
2014 |
|
Childhood Acute Lymphoblastic Leukemia
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Expression of HDAC1-11 was determined in 93 primary ALL and eight healthy donor samples.
|
23948281 |
2013 |